Skip to main content

IntegriChain Execs to Address 340B, Gross-to-Net at Fall Summits

Image
IntegriChain Execs to Address 340B, Gross-to-Net at Fall Summits

Philadelphia – September 22, 2026 -- IntegriChain will send five senior advisors to three Informa Connect industry conferences this fall, addressing government pricing, 340B compliance, and gross-to-net forecasting for biopharma manufacturers navigating tightening reimbursement rules.

Government pricing experts present at Chicago's MDRP Summit in October

At the Medicaid Drug Rebate Program (MDRP) Summit 2026, running October 5-7 at the Fairmont Chicago Millennium Park, Jeff Baab, Partner of Advisory Services at IntegriChain, will present "Updates on Landscape of Government Pricing and Contracting" on October 7 at 9:40 AM. The same day at 10:50 AM, Clay Willis, also Partner of Advisory Services, will deliver "340B Movement to Have All 340B Claims in One System of Record," covering the rebate model pilot program #2 and updated patient-definition and contract-pharmacy policies.

Philadelphia's GTN Summit in November draws two IntegriChain leaders

At the Pharma/Biotech Gross-to-Net (GTN) Summit 2026, held November 16-18 at the Hilton at Penn's Landing in Philadelphia, Jennifer Sharpe, Vice President of Gross-to-Net Consulting, will moderate a roundtable on November 16 at 4:30 PM for members of IntegriChain's Revenue Analytics Collaborative, a peer network of more than 800 industry participants she co-founded. On November 17 at 10:55 AM, Walt Worsham, Managing Director at IntegriChain, will present regulatory updates tied to gross-to-net forecasting, accruals, and contracting strategy.

December keynote to examine pharmacy and distribution disruption

At Trade & Channel Strategies 2026, taking place December 8-10 at the W Hotel in Philadelphia, Bill Roth, Senior Vice President and Managing Partner of Consulting and Advisory at IntegriChain, will deliver a keynote on channel disruption, addressing reimbursement pressure at national retail pharmacy chains and downstream effects on specialty and general medicine brands.

"Government pricing, 340B, gross-to-net, and trade and channel strategy are more interconnected and more consequential than ever for our clients," said Baab.

Published by
fairsonline_team
Industries
News Type